Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.2, while Novo Nordisk A/S trades at $46.46 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $63.98 |
52-Week Low | $17.80 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.20, up 0.72% with a bearish technical outlook indicated by moving averages. The ETF generates weekly dividend distributions but faces significant price depreciation concerns highlighted in recent financial media coverage. Current RSI levels suggest potential oversold conditions while the stock tests key support at $18.
The outlook remains challenging with negative sentiment surrounding the ETF's strategy and performance. While high dividend yields attract income investors, the underlying price erosion presents substantial risk. Analyst commentary questions the sustainability of returns amid ongoing capital depreciation.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
